Welcome to Retina Research Center
"Our mission is to provide first-class, compassionate care for our patients with retinal diseases using the latest technologies and techniques available. We are committed to the advancement of clinical medicine and recognize its impact on those it benefits most: our patients."
Office Hours: 8:00 a.m. - 5:30 p.m.
November is National Diabetes Month
Austin Medical Plaza
The Retina Research Center is a dedicated research facility founded by Brian Berger, M.D. in 1999. Our medical staff has been performing a variety of clinical trials for over ten years. Since 1999 we have participated in clinical trials focusing on age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, surgical procedures and devices, and uveitis. We also perform retinal exams for local research sites administering systemic medications. Under the direction of Dr. Brian Berger, Dr. Isaac Loose, and Dr. Stephen Whiteside, our site enrolls patients from an extensive patient base referred by many private practices within Austin and the surrounding areas. Our clinical research coordinators and ophthalmic technicians are friendly, knowledgeable, certified, and look forward to helping you and your family receive the newest treatments for retinal diseases.
Dr. Berger received the Castle Connally Top Doctors award in 2012.
Dr. Berger was acknowledged in the January 2013 issue of the Austin Monthly magazine as one of the "Top Doctors 2013"
Like us on Facebook !
Retina Research Center participates with Ampio Pharmaceuticals investigating oral Optina for the treatment of diabetic macular edema.
Dr. Berger Voted Top Doctor in Austin
Research Press Releases
Retina Research Center participates in first clinical trial to show positive results in advanced age-related macular degeneration RESULTS
Retina Research Center conducts Austin's only Dry Age-Related Macular Degeneration Trial
NOW FDA APPROVED: JETREA Intravitreal Injection is a proteolytic enzyme indicated for the treatment of symptomatic vitreomacular adhesion.
ILUVIEN receives European approval
Phase I study with novel approach to Wet Age-Related Macular Degeneration now complete
A treatment breakthrough for saving the vision of people with diabetic macular edema